Scott Kopetz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the growing prognostic and clinical value of circulating tumor DNA (ctDNA) in solid tumors. He highlights the role of ctDNA in assessing treatment response, identifying minimal residual disease (MRD), and guiding personalized treatment strategies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.a